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REVIEW
Abstract: RETAANE® 15mg (anecortave acetate suspension) is under investigation to treat
exudative age-related macular degeneration (AMD), the single largest cause of blindness in
the Western world, affecting over 15 million people in the USA. RETAANE suspension is a
unique synthetic cortisene and has antiangiogenic properties that were established in multiple
experimental models of angiogenesis. The molecule acts at multiple sites of the angiogenic
cascade. Clinical trials in patients with exudative AMD have demonstrated the excellent safety
record of both the drug anecortave acetate and the posterior juxtascleral depot (PJD)
administration procedure. A pivotal study comparing RETAANE suspension with placebo
showed a significantly higher chance of maintaining vision in the treatment (73%) as compared
with placebo (47%). Another study compared RETAANE suspension with Visudyne®
photodynamic therapy, revealing no statistically significant differences between the two
treatments over 24 months. AMD is a multi-faceted disease and therefore a molecule such as
RETAANE suspension with a unique mechanism of action, demonstrated clinical efficacy,
and retreatment every six months is an important potential treatment option which should be
further investigated both as a monotherapy or in combination with other treatment strategies.
Keywords: age-related macular degeneration (AMD), anecortave acetate, RETAANE
suspension, exudative AMD, progression of dry AMD
Introduction – current treatment options
Age-related macular degeneration (AMD) is the most serious threat to the vision of
the elderly. It is the leading cause of severe and permanent central vision loss amongst
those over 50 (Swann and Lovie-Kitchin 1990). About 10% of the population over
the age of 52 and up to 33% of those over 75 present with any signs of AMD. Over
15 million Americans are already afflicted with a form of the disease and the number
is rising at the rate of 2 million new cases every year. According to the European
office of AMD Alliance International, an estimated 2.8 million cases of wet AMD
will be diagnosed in the 25 European countries within the next decade. With such an
imminent threat to the vision of the elderly, significant research and development
efforts are being devoted to finding effective treatment methods for wet AMD.
Currently available treatments include laser photocoagulation, verteporfin
photodynamic therapy (PDT) (Visudyne
®, Novartis AG, Basel, Switzerland),
pegaptanib sodium injection (Macugen
®, Eyetech Pharmaceuticals/Pfizer), and
anecortave acetate (RETAANE
® suspension, Alcon Laboratories, Inc., Fort Worth,
Texas, USA). In addition, modified PDT treatments such as the combination of PDT
with intravitreal triamcinolone became very popular within the last year (Augustin
and Schmidt-Erfurth 2006).
Anecortave acetate is a promising new treatment option that is being clinically
tested and recently approved in Australia for treating AMD patients with classic
containing lesions. Until 2000, laser photocoagulation was the only approved
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treatment for choroidal neovascularization (CNV). Although
effective in ablating CNV and attenuating vision loss over
time, laser photocoagulation may be cytodestructive to
retinal neurons and can result in an immediate and permanent
loss of vision in the treated area, a trade-off unacceptable to
many patients considering the procedure. Verteporfin PDT
(Visudyne) was approved in 2000 following the
demonstration that the procedure was effective in attenuating
the rate of vision loss in AMD patients with classic
containing lesions. The necessity of retreatments led to the
investigation of combination strategies in multiple case
series and different lesion types. Those combination
approaches are now used by many clinicians on a routine
basis (Augustin and Schmidt-Erfurth 2006).
During the approval process, various pharmacological
agents found to be effective in retarding vessel growth in
animal models of ocular neovascularization were
subsequently evaluated in AMD patients for inhibiting CNV
growth and preservation of vision. In December, 2004,
Macugen, an aptamer inhibiting vascular endothelial growth
factor (VEGF) became the first pharmacological agent to
be approved for treatment of CNV in all lesion subtypes in
patients with exudative AMD.
At one year, Macugen was demonstrated to be more
effective than sham injection at preserving vision. Patients
treated with Macugen 0.3 mg had a 10% risk of experiencing
severe vision loss (≥6 lines of vision) compared with 22%
in the sham-injection group. Also at one year, 70% of
patients in the treatment group had preserved vision
compared with 55% in the sham-injected group (Gragoudas
et al 2004). At the two year endpoint Macugen demonstrated
a 45% treatment effect (difference between sham and active
groups with less than 3 lines of lost vision). Subsequent
approval of Macugen is expected in Europe in early 2006.
Other pharmacologic interventions for wet AMD
including the VEGF inhibitor Ranibizumab (Lucentis
®), and
RETAANE, an angiostatic cortisene, are in late stages
of clinical development/approval. Additionally, non-
pharmacological approaches including transpupillary
thermotherapy, radiation therapy, and surgical intervention
are still being clinically evaluated. Table 1 summarizes
available and potential AMD treatment options. However,
the results of those approaches are less promising as
compared with drug therapies of this disease entity.
Pathophysiology of wet AMD
AMD is a complex, multi-faceted disease. While the
definitive cause has not been elucidated, epidemiological
studies have identified several risk factors. Age is by far the
most prominent risk factor for AMD among males and
Table 1 CNV therapies currently approved or under clinical development
Therapy Active ingredient Company/sponsor Type Stage
Visudyne Verteporfin Novartis PDT Approved
Macugen Pegaptanib sodium Eyetech/Pfizer Anti-VEGF Approved
RETAANE Anecortave acetate Alcon Angiostatic cortisene Approved in
Australia*
Kenalog Triamcinolone acetonide Bristol Meyers Squibb Corticosteroid Used off label
Avastin Bevacizumab Genentech Anti-VEGF Used off label
Lucentis Ranibizumab Genentech Anti-VEGF NDA filed
Photrex Rostaporfin Miravant PDT Phase III
Evizon Squalamine lactate Genaera Anti-angiogenic small molecule Phase III
Cand5 siRNA Acuity Pharma Inhibits VEGF mRNA Phase II/III
Retisert Fluocinolone acetonide Bausch & Lomb Corticosteroid Phase II
Celebrex with PDT Celecoxib NEI Anti-angiogenic & anti-inflammatory Phase II
Thalidomide Thalidomide Celgene Anti-angiogenic small molecule Phase II
CA4P Combretastatin A4 phosphate Oxigene Vascular targeting agent Phase I/II
(for  MMD)
Vatalanib with PDT Vatalanib Novartis Anti-VEGF and PTK inhibitor Phase I/II
Talaporfin with PDT Talaporfin sodium Light Sciences PDT Phase I
VEGF trap VEGF Trap Regeneron VEGF receptor decoy Phase I
AdPEDF Adenovirus vector GenVec Anti-angiogenic protein Phase I
siRNA-027 siRNA SiRNA Therapeutics Inhibits VEGF receptor mRNA Phase I
NT-501 Ciliary Neurotrophic factor Neurotech Encapsulated cell therapy Phase I
Note: *Global approval process is ongoing.
Abbreviations: adPEDF, adenoviral pigment-epithelium-derived factor; CNV, choroidal neovascularization; mRNA, messenger ribonucleic acid; NEI, National Eye
Institute; PDT, photodynamic therapy; PTK, protein tyrosine kinases; siRNA, small interfering ribonucleic acid; VEGF, vascular endothelial growth factor.Clinical Interventions in Aging 2006:1(3) 239
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females. Other risk factors associated with AMD include
presence of soft drusen, macular pigmentary changes, CNV
in the fellow eye, race, genetic predisposition, gender, iris
color, obesity, and smoking (Table 2).
Much is now known about the process for developing
CNV in the wet (exudative) form of the disease. The
multifaceted process of neovascularization can be broken
down into several distinct stages (Clark 1997). A
proangiogenic signal associated with late stage disease
stimulates the production of trophic factors that initiates the
growth of new blood vessels. The signal to release such
growth factors is still speculative and may relate to hypoxia
or inflammation associated with remodeling of the outer
retina with immunologic phenomenons being involved as
well (Kijlstra et al 2005). Synthesis of a variety of
proangiogenic trophic factors has been proposed; with
greatest evidence pointing to VEGF as an initiator of
proliferation of CNV and subsequent vascular leakage. The
trophic factors have been demonstrated to bind to receptors
on vascular endothelial cells (VECs), leading to activation
of genetic machinery leading to the production and release
of enzymes such as matrix metalloproteinases (MMPs),
which degrade the basement membrane and extracellular
matrix which surrounds the VECs. Degradation of the
extracellular matrix has been shown to be a prerequisite for
proliferation and migration of VECs and subsequent tube
formation, the result of which leads to the establishment of
an immature blood vessel. With the development of a new
basement membrane, the new capillary is stabilized and is
capable of transporting blood through its lumen (Figure 1).
Anecortave acetate – chemical
properties, mechanism of action
New compounds known as cortisenes were discovered in
1985 and were found to have angiostatic properties in simple
in vitro models of angiogenesis. These steroid-like
compounds are devoid of clinically relevant glucocorticoid
activity and therefore do not elevate IOP or cause cataracts
(Crum et al 1985). Further research led to the identification
of anecortave acetate which is an antiangiogenic analog of
cortisol (Blei et al 1993).
Anecortave acetate differs in structure from cortisol by
the removal of 11-beta hydroxyl, addition of a double bond
at the C9-11 position, and addition of an acetate group at
the C21 position to enhance bioavailability. The resulting
molecule is an angiostatic cortisene that imparts angiostatic
activity, but does not exhibit typical glucocorticoid-receptor-
mediated activity (Figure 2). Anecortave acetate
demonstrated a broad range of antiangiogenic properties in
both in vitro and in vivo models of ocular neovascularization
(Table 3).
In vitro data indicated that the proliferation of cultured
human VECs is inhibited by anecortave acetate. Anecortave
Table 2 Summary of significant risk factors for age-related
macular degeneration
Known risk factors Study
Age Klein et al 1992; Vingerling et al 1995
Smoking Christen et al 1996; Seddon et al 1996;
Vingerling et al 1996
Exposure to large Hamm et al 1976; Taylor et al 1990
quantities of visible
spectrum, particularly
blue light
Nutrition and dietary habits Seddon et al 1994
Zinc Newsome et al 1998
High Intake of dietary fats Seddon et al 2001
Hypertension Abdelsalam et al 1999
Figure 1 Schematic diagram of the anecortave acetate, a unique synthetic cortisene. Modifications made to the cortisol parent molecule are shown.
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acetate’s mechanism of action is in part through inhibiting
the expression of urokinase plasminogen activator (uPA)
and matrix metalloproteinases (MMPs), extracellular
proteases necessary for the breakdown of the basement
membrane and extracellular matrix necessary for subsequent
migration of VECs into tissue stroma during blood vessel
growth (DeFaller and Clark 2000). Additionally, anecortave
acetate has been demonstrated to stimulate the production
of plasminogen activator inhibitor-1 (PAI-1), a specific
inhibitor of uPA activity (Penn et al 2001) (Figure 5). In a
rat model of retinopathy of prematurity (ROP) retinal levels
of PAI-1 and mRNA increased 6- to 9-fold in 24 to 72 hours
following intravitreal injection of anecortave acetate
(BenEzra et al 1997). Administration of anecortave acetate
inhibits the activities of uPA and MMPs. As a result,
proteolysis necessary for cellular migration cannot occur
and angiogenesis is thus inhibited. Primary angiostatic
effects of anecortave acetate on trophic factor release have
been demonstrated as well. In one study using the rat ROP
model, anecortave acetate reduced the expression of the
proangiogenic insulin-like growth factor (IGF-1) and IGF-
1 receptor by 36.9% and 50.5%, respectively (Liu et al
2005). In a similar series of experiments using the same rat
ROP model, injection of anecortave acetate also reduced
VEGF protein at one and two days post-oxygen exposure.
This model also demonstrated that anecortave acetate
inhibited the transcription of VEGF mRNA, which is
upregulated during angiogenesis (Yang et al 2005). Future
studies are on-going to quantify specific VEGF mRNA
splice-variants (Figure 1).
Table 3 Summary of the in vitro and in vivo models of neovascularization used to evaluate the antiangiogenic properties of
anecortave acetate
Models References
Human vascular endothelial cells  Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Chicken embryo CAM McNatt et al 1999; Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003 
Rabbit corneal NV BenEzra et al 1997; McNatt et al 1999; Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Retinal NV in newborn mice Clark 1997; Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Light-induced retinal NV in RCS rats Clark 1997; Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Murine intraocular tumor  Clark et al 1999; Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Kitten retinopathy of prematurity Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Rat pup retinopathy of prematurity Clark et al 2000; DeFaller and Clark 2000; Penn 2001; Clark and Penn 2003; Clark and Yorio 2003 
Mouse laser-induced choroidal NV Clark 1997; Clark et al 2000; DeFaller and Clark 2000; Clark and Penn 2003; Clark and Yorio 2003 
Rabbit choroidal NV Clark et al 2000; DeFaller and Clark 2000; Clark and Yorio 2003
Abbreviations: CAM, cell-adhesion molecule; NV, neovascularization; RCS, Royal College of Surgeons.
Figure 2 The unique design of the blunt tinted posterior juxtascleral depot cannula ensures that anecortave acetate is delivered directly behind the macula while
leaving the globe intact.Clinical Interventions in Aging 2006:1(3) 241
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Posterior juxtascleral depot (PJD)
Topical ocular administration and subconjunctival
administrations of anecortave acetate did not achieve
sufficient concentration of the drug to inhibit angiogenesis
in the retina and choroid. Intravitreal injections of anecortave
acetate provide therapeutic levels of the drug to the retina;
however, routine intravitreal injections were undesirable due
to the potential for serious complications such as
endophthalmitis and retinal detachment and overall
discomfort of the patient.
Sub-Tenon’s injections with a straight needle were found
to provide therapeutic drug concentrations (≥0.1 uM) in both
the retina and choroid, but these injections were highly
variable in their placement. Poor drug positioning would
result in an undesirably high incidence of treatment failures
due to low drug bioavailability; therefore, a specialized
cannula and depot delivery technique were developed for
the administration of RETAANE.
A 56-degree curved posterior juxtascleral cannula was
developed to follow the curvature of the globe during
insertion, underneath the conjunctiva and Tenon’s capsule,
on bare sclera. It has a length that positions the tip directly
behind the macula when it is fully inserted. The globe is not
perforated during the procedure. The orifice of the cannula
is located on the inferior surface of the tip to assure
administration of anecortave acetate in direct apposition to
the scleral surface (Figure 3).
In contrast to the traditional sub-Tenon’s injections
which missed the targeted area nearly 30% of the time,
injections using posterior juxtascleral depot (PJD) delivered
the entire dose over the macular region and directly onto
the scleral surface. PJD administration results in no risk of
endophthalmitis, retinal detachment, or IOP increase
because the globe is not penetrated during administration.
In clinical studies PJD resulted in no clinically relevant
treatment-related adverse events and due to our current
knowledge, re-administration of anecortave acetate is only
required every 6 months.
In the clinical studies it has been shown that anecortave
acetate can reflux out the cannula incision during the PJD
procedure. To address this issue, a counter pressure device
(CPD) has been developed by the manufacturer of the drug
to stop the reflux of the suspension, ensuring that the
complete quantity of drug is delivered behind the macula.
The CPD is positioned as posterior as possible from the
incision site, perpendicular to the globe. The notch on the
CPD straddles the cannula over the conjunctiva, which
allows the procedure to be completed by one person and
Table 4 Percentages of adverse events attributed to the
posterior juxtascleral administration or sham procedure
Anecortave Sham
acetate group
groups
Ptosis 20% 20%
Ocular pain 20% 17%
Subconjunctival hemorrhage 13% 17%
Ocular pruritis 13% 27%
Figure 3 The counter pressure device prevents reflux of anecortave acetate when placed as posterior as possible in position with the posterior juxtascleral depot
cannula.Clinical Interventions in Aging 2006:1(3) 242
Augustin
also increases stability. Studies on bioavailablility have
been performed to further address this issue. Those
studies have shown that patients that did not have reflux
had greater systemic bioavailability as assessed by higher
plasma concentrations of anecortave acetate (please see
Figure 5).
Finally, the PJD procedure does not require immediate
follow-up visits and no safety issues with the procedure have
been identified (Figure 3).
The PJD procedure has been used in clinical trials to
deliver more than 2500 juxtascleral depots in nearly 900
patients with no safety concerns reported (Regillo et al
2005). Some patients have received as many as seven
PJD administrations. To date, no globe perforations,
damage to the optic nerve, damage to posterior ciliary
arteries, or other significant concerns regarding the
cannula have been raised by investigators during studies.
The adverse events most often attributed to the PJD
administration procedure in all treatment groups are
shown in Table 4.
No events associated with PJD were serious, almost all
were mild and transient, with similar frequency across all
groups, and did not interrupt treatment (D’Amico et al 2003;
Augustin et al 2005).
Clinical trials
C-98-03: dose-response monotherapy
study: RETAANE 15 mg (anecortave
acetate suspension) or anecortave
acetate (3 mg, 30 mg) versus placebo in
AMD patients
One hundred twenty eight patients with exudative subfoveal
AMD were enrolled in a double-masked, dose-response
study, beginning in 1999, to evaluate the safety and efficacy
of anecortave acetate. Patients were randomized to receive
anecortave acetate (30 mg, 15 mg, or 3 mg) or placebo via
PJD administration every six months for a total of 24 months.
The primary efficacy variable was the mean change from
baseline in best-corrected ETDRS logMAR visual acuity.
The secondary efficacy outcomes were: (a) preservation of
vision (loss of less than three lines), (b) clinically significant
worsening of vision (loss of at least three lines), (c) severe
vision loss (loss of at least six lines), and (d) changes in
CNV.
The efficacy of anecortave acetate 15 mg for
maintaining vision and suppressing lesion growth in
patients with exudative AMD have been confirmed by
long-term study results. Anecortave acetate 15 mg was
Figure 4 Evidence supports use of counter pressure device (CPD) for managing reflux. Plasma concentrations of anecortave desacetate in patients with the CPD (C-
04-50) were the same as the plasma concentrations in patients without the CPD and had no reflux (C-02-47). Patients (C-02-47) with reflux had 4 fold lower levels
of anecortave desacetate than patients without reflux. In the C-04-50 study, the CPD prevented reflux in 100% of the patients.
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superior at month 24 to other dosages tested and
statistically superior to placebo in preserving visual acuity
(p≤0.05). In the anecortave acetate group, 73% of patients
maintained vision compared with 47% in the sham group.
In the sham-treated group 23% of patients went on to
severe vision loss compared with 6% in the anecortave
acetate treated group (p≤0.05). Anecortave acetate also
demonstrated the ability to inhibit the growth of classic
CNV (p≤0.05) in eyes with all lesion types. Beginning at
six months and continuing throughout the entire 24-
month study, anecortave acetate 15mg was consistently
more effective in stabilizing vision compared with
placebo.
The following mild and transient conditions were noted
post administration: ptosis, subconjunctival hemorrhage,
ocular discomfort, ocular pruritus, hyperemia, and foreign
body sensation (see also Table 4).
The clinical efficacy observed in this study of a mixed
population of AMD lesion types and sizes supports earlier
observations that anecortave acetate is likely to inhibit CNV
lesion growth regardless of lesion subtype.
C-00-07: anecortave acetate suspension
and PDT combination trial
C-00-07 was a 6-month phase II study that evaluated the
effect of anecortave acetate (15 mg or 30 mg) versus placebo
following initial Visudyne PDT, for the treatment of patients
with exudative AMD. This study enrolled 136 patients and
was completed in 2002. Patients who received a single
administration of anecortave acetate following initial
treatment with PDT maintained better vision than patients
who received PDT alone. Data from this study illustrated
that anecortave acetate can be safely administered with PDT.
C-01-99: pivotal study versus Visudyne
PDT: RETAANE suspension plus sham
PDT versus Visudyne PDT plus sham PJD
This pivotal, non-inferiority study was designed to compare
anecortave acetate 15 mg suspension to PDT with
verteporfin. The 530 exudative AMD patients enrolled in
this study were randomized 1:1 to either a PJD
administration of anecortave acetate 15 mg every six months
combined with a sham PDT treatment every three months
per labeling guidelines, or to PDT every three months
combined with a sham PJD administration every six months.
This trial confirmed the excellent safety results reported in
C-98-03 study. At 12 months 45% of anecortave acetate
15 mg-treated patients had preserved vision compared with
49% in the PDT group (p>0.05) which was not significantly
different (Slakter et al 2006). The study demonstrated that
anecortave acetate and verteporfin PDT treatments are
clinically equivalent throughout 24 months following
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Figure 5 Anecortave acetate blocks proteolytic cascade in the vascular endothelial cells (VEC).Clinical Interventions in Aging 2006:1(3) 244
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treatment with respect to the percentage of patients with
<3 line loss of logMAR visual acuity. The largest
difference between the two treatment groups at 12 and
24 months was 3.5 letters which is not clinically
significant. However, the drug did not meet the primary
endpoint, which led to a further evaluation of the study.
This led to interesting results regarding the reflux problem
and treatment intervals which had a significant impact
on the data. The primary endpoint would have been met
with the statistical evaluation being performed with data
from predominantly classic lesions only, which is the only
lesion composition of the study population. This issue is
extensively discussed by Slakter and coworkers (2006).
Furthermore, in a subsequent pharmacokinetic study, C-
02-47, investigators looked at correlations between drug
reflux and plasma levels of anecortave acetate and
showed that there was a 4-fold lower plasma level of the
drug in the eyes that experienced reflux.
When considering only those patients that did not have
reflux in the C-01-99 study, the percentage of patients in
whom vision was preserved increased from 45% to 50%.
When data from patients who experienced reflux and re-
treatment after 6-months were excluded, 57% of anecortave
acetate 15 mg-treated patients had preserved vision.
In this study it was noted that the degree of preservation
of vision for both anecortave acetate 15 mg (45% with <3-
line vision loss) and PDT was considerably less than
previously observed in other trials including C-98-03 and
the TAP study. Analysis of baseline data reveals that the
lesions in this study were significantly smaller and younger
at baseline than those in previous studies and included a
high proportion of lesions with a retinal angiomatous
proliferation (RAP) component. The high incidence of
characteristics such as RAP, extensive subretinal
hemorrhage/fluid and subfoveal hotspots along with the fact
that these lesions were diagnosed early in the disease
suggests that this study included unusually aggressive
lesions (Slakter et al 2005).
C-02-47: pharmacokinetics of
RETAANE suspension in patients with
AMD
This was a pharmacokinetics (PK) study in 20 patients with
wet AMD who had two PJD administrations of RETAANE
suspension over a 12 month period. The peak plasma levels
were correlated with observed reflux. It was found that the
patients for whom reflux was observed had plasma levels
that were 4-fold lower than patients without reflux. These
results highlighted the need for a CPD.
C-04-50: pharmacokinetics and reflux
study with counter pressure device
Recognizing the need for a method to reduce reflux, the
manufacturer of anecortave acetate (Alcon Laboratories,
Inc.) initiated this study to determine the ability of a CPD
to eliminate reflux. The study was done at the request of the
FDA. This pharmacokinetic study was undertaken to
determine whether reflux could be prevented and used serum
drug levels as a quantitative, surrogate measure for the
influence of reflux on drug absorption. Investigators
evaluated and scored drug reflux following administration
of RETAANE.
Reflux was effectively controlled in 100% of patients,
with a reflux score of 0 for all eyes (as rated by the
investigator), consistent with no loss of dose upon
administration using the CPD. Mean plasma drug levels
were increased 4-fold over drug levels observed with reflux
in the C-02-47 trial. Controlling reflux with the CPD is
expected to provide improved visual acuity outcomes based
on improved outcomes in patients without reflux in protocol
C-01-99 relative to those with reflux (Figure 4).
C-02-60: the anecortave acetate risk
reduction trial.
Several studies have shown that patients with wet AMD in
one eye are at high risk of developing CNV in the fellow
eye with dry AMD. It was found that patients with both
large drusen (larger than 63 µm) and retinal pigment
epithelium hyperpigmentation in the fellow eye faced a 58%
risk of developing CNV within 5 years. By comparison,
patients without large drusen or hyperpigmentation in their
fellow eye faced a much lower (10%) risk of developing
CNV (Abdelsalam et al 1999). Another study found that if
the fellow eye had 5 or more large drusen, it was more than
twice as likely to develop CNV compared with a fellow eye
with fewer or no drusen. The chances of CNV development
were also found to be higher in eyes with confluent drusen
and focal areas of hyperpigmentation. Amongst the 670
patients observed in this study, 236 (35%) developed CNV
in the better eye within 5 years (BenEzra et al 1997).
These epidemiological studies have provided the
baseline data necessary for undertaking clinical trials
studying prevention of wet AMD. The studies using this
clinical model are extremely costly due to the large numbersClinical Interventions in Aging 2006:1(3) 245
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of patients that must be enrolled to have a reasonable
probability of detecting a statistical difference between the
treatment groups and the follow-up period is usually long.
The Anecortave Acetate Risk Reduction Trial (AART)
was designed to demonstrate that anecortave acetate
suspension (15 mg or 30 mg) is safe and effective in arresting
the progression of non-exudative (dry) AMD in patients who
are at-risk for progressing to exudative (wet) AMD. The
primary outcome measure of this study is the percentage of
patients with sight-threatening CNV in the study eye at
month 48. The study is being conducted at over 100 centers
across the US, Europe, Australia and South America.
Enrollment of more than 2500 patients was completed at
the end of 2005.
Role of RETAANE
As discussed above, RETAANE suspension is an effective
and safe treatment for patients with wet AMD. Use as
monotherapy is supported by the dose-response study (C-
98-03) comparing efficacy of RETAANE 15 mg versus
placebo and the demonstration of equivalence of RETAANE
15 mg and Visudyne PDT over 24 months (C-01-99). An
alternative role for RETAANE 15 mg as an adjunct or in
combination to anti-VEGF therapy may be considered
because of its unique, multifactorial mechanism of action,
6 month duration of action and safety due to the PJD
procedure. In addition, RETAANE suspension has been
demonstrated to be safe for use with Visudyne PDT (see C-
00-07 above). Not known at this time is whether RETAANE
15 mg given by PJD administration can potentiate the
efficacy of intravitreal anti-VEGF therapy and reduce the
frequency of intravitreal injections associated with the anti-
VEGF approach. To further address this interesting issue,
Alcon Research Ltd., is collaborating with the National Eye
Institute to conduct the BRIDGE Study which is a
randomized, masked, multi-center, phase II study of the
effect of PJD delivery of RETAANE 15 mg on the response
to intravitreal bevacizumab (Avastin™) in patients with
subfoveal CNV secondary to AMD. The objective of this
study will be to investigate whether RETAANE 15 mg
(anecortave acetate suspension) reduces the frequency
of intravitreal injections while maintaining vision and
limiting disease progression in patients who are receiving
intravitreal injections of bevacizumab (Avastin) for
treatment of exudative AMD. Finally, due to the
characteristics of RETAANE suspension (ie, mechanism
of action, safety, and chronic duration following PJD
administration), the drug may be suited for arresting the
conversion of dry AMD to wet AMD in patients at risk
for developing CNV associated with AMD (AART
Study). If approved for arresting the progression of CNV,
RETAANE 15 mg would be the only therapy, with the
exception of AREDS vitamin supplement, to inhibit
progression of any AMD subtype.
Regulatory status
RETAANE suspension was approved in Australia on
December 12, 2005. On May 24, 2005 the US Food and
Drug Administration (FDA) issued an approvable letter for
the RETAANE 15mg (anecortave acetate suspension) new
drug application (NDA).
In March 2006, Alcon has withdrawn the application
for approval at the European Medicines Agency (EMEA).
Conclusion
A synthetic cortisone (anecortave acetate) has been shown
to have antiangiogenic properties that have been established
in multiple experimental models of angiogenesis. Clinical
trials in patients with exudative AMD have demonstrated
an excellent safety record both for anecortave acetate and
the PJD administration, with no clinically relevant adverse
events.
Co-administration of anecortave acetate 15 mg with PDT
has been shown to be safe. Patients receiving one anecortave
acetate administration and one PDT treatment showed a
trend toward better visual outcomes than patients receiving
multiple PDT treatments. In addition, treatment with
anecortave acetate 15 mg reduced the need for future PDT
treatments.
AMD is viewed as a multifactorial disease by most
retina specialists, and as such it is likely that a
combination of drugs will result in a better visual acuity
outcome than a mono-therapy approach in this disease.
In addition, a second goal of all new treatment strategies
is the reduction of retreatments being necessary for a
complete regression of the CNV. With its mechanism of
action, excellent safety profile, and innovative delivery
method once every six months, RETAANE suspension
may function to assist not only in controlling the CNV
either alone or as a component of combination therapy,
but also as a treatment for reducing the risk of the
development of wet AMD. The results from the AART
study could thus be an important milestone for AMD
treatment options.Clinical Interventions in Aging 2006:1(3) 246
Augustin
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